Article
Durvalumab after concurrent chemoradiotherapy for sensitizing epidermal growth factor receptor-mutant stage III non-small cell lung cancer: A Japanese Real-World data analysis.
Lung cancer (Amsterdam, Netherlands) - 1 Jul 2025
Fujisaki Toshiya, Miyauchi Eisaku, Kida Gen, Miura Yu, Watanabe Kana, Ashinuma Hironori, Tamiya Motohiro, Kikuchi Hajime, Arai Daisuke, Takahashi Satoshi, Masuda Ken, Takigami Ayako, Nagai Yoshiaki, Miyawaki Taichi, Tsubata Yukari, Nakao Akira, Masubuchi Ken, Nishiyama Kazuhiro, Watanabe Satoshi, Morita Satoshi, Maemondo Makoto
Abstract excerpt
INTRODUCTION: In locally advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), the efficacy and safety of durvalumab after concurrent chemoradiotherapy (CCRT) remain controversial. METHODS: In this retrospective cohort study, we analyzed treatment outcomes in patients with unresectable stage III sensitizing EGFR-mutant NSCLC who underwent and completed CCRT without...
Read the complete abstract on PubMedTopics
- Humans
- Carcinoma, Non-Small-Cell Lung
- Male
- Female